Jin Fang Medicine-B (02595): The registration clinical trial of GFH375 for the treatment of metastatic pancreatic cancer has been initiated at the first research center. This is the world's first phase III study of an oral KRAS G12D inhibitor as monotherapy compared to chemotherapy.

Zhtng cijng APP news, Jn fng yyo-B (02595) fb gnggo, kuf KRAS G12D (ON/OFF) yzhq GFH375 zhlio Jngzh KRAS G12D tbin xng zhunyxng pncreatic cancer hnbng de zhcxng III q shyn (GFH375X1301) y zi bijng dxu zhngliu yyun qdng. Mqin GFH375 kif jnd wiy qunqi kuf KRAS G12D yzhq d y tdu, duxing GFH375 (y zhnggu jngwi chng VS-7375) dn yo h linh liof zhngzi zhnggu (yu jn fng zhdo) j hiwi (yu jn fng hzuhubn Verastem Oncology zhdo) jnxng lnchung tnsu, boku GFH375 linh hulio (bidnbi zshng sn h j x t bn, AG) yxin zhlio wnq pncreatic canal ndnzhn kncn (PDAC); cwi GFH375/VS-7375 y hud FDA kuis tngdo zling rndng, zhlio gxin jb wnq j zhunyxng KRAS G12D tbin xng PDAC hnbngzh.